KIT and neuroblastoma: Several RTKs, including ALK, KIT, MET, NTRK2, and RET, play a major role in neuroblastoma pathogenesis [70,71,72], and their activation could be responsible for adaptive resistance to trametinib and ganitumab in neuroblastoma.